Obstructive Hypertrophic Cardiomyopathy clinical trials at UCSF
1 in progress, 1 open to new patients
Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
open to eligible people ages 18 years and up
This is a multicenter, international, double-blind study of the administration of mavacamten in participants with symptomatic obstructive HCM (oHCM). Approximately 220 participants will be randomized to receive placebo or mavacamten.
San Francisco, California and other locations